Zadaxin thymosin alpha 1 data

SCLN (San Mateo, Calif.) reported interim data of its 18-month trial in Taiwan, which enrolled the last of 158 patients this month. Laboratory data from 18 patients, who had completed 12 months of the protocol, were presented at the Montgomery Securities Conference.

Five of six patients in each of two treatment groups (12 months of drug, and six months of drug followed by six months of observation, respectively) were negative for hepatitis B DNA. Two of six control subjects (observation only) were HBV DNA negative. ...